How should ornithine deficiency be diagnosed and treated?

Ornithine Transcarbamylase Deficiency: Diagnosis and Management

Immediate Recognition and Diagnosis

Ornithine transcarbamylase (OTC) deficiency should be suspected in any patient presenting with unexplained encephalopathy, elevated ammonia levels, and respiratory alkalosis, particularly when triggered by protein intake, fasting, surgery, or medications like valproic acid. 1, 2

Clinical Presentation Patterns

• Neonatal-onset males typically present within the first few days after feeding begins with lethal hyperammonemia when all enzyme activity is abolished 1, 2
• Late-onset patients (both males and heterozygous females) present after infancy with episodic hyperammonemia triggered by metabolic stress, with median onset age around 3.6 years but can occur as late as the sixth decade 3, 4
• Key symptoms include progressive lethargy, confusion, vomiting, coma, seizures, irritability, and decline in language ability 5, 6, 3
• Important clue: voluntary adoption of a vegetarian diet in asymptomatic patients suggests subclinical disease 2

Diagnostic Workup

Plasma ammonia >200 µmol/L is linked to poor neurological outcomes including cerebral edema and death, making rapid diagnosis critical. 1

• Biochemical testing reveals elevated urinary orotate and uracil with normal or low plasma citrulline, distinguishing OTC deficiency from other urea cycle disorders 6, 3
• Blood amino acid analysis and urine organic acid analysis via gas chromatography-mass spectrometry are essential first-line metabolic screens 7, 6
• Genetic confirmation through OTC gene sequencing (located on Xp21.1) establishes definitive diagnosis and enables family screening 2, 3
• Brain MRI shows characteristic patterns consistent with urea cycle disorders and reflects the degree of brain injury 6
• Liver biopsy with enzyme assay can be considered when genetic testing is inconclusive 2

Acute Hyperammonemic Crisis Management

Immediately discontinue all oral feeds and initiate treatment without waiting for confirmatory testing when elevated ammonia is detected. 8

Nutritional Support (First 48 Hours)

• Provide ≥100 kcal/kg daily as intravenous glucose and lipids to prevent catabolism-driven ammonia production 8
• Maintain glucose infusion rate of 8–10 mg/kg/min 8
• Administer lipids starting at 0.5 g/kg daily, up to 3 g/kg daily 8
• Gradually reintroduce protein by 0.25 g/kg daily increments up to 1.5 g/kg daily within 48 hours once ammonia stabilizes; delaying protein beyond 48 hours drives further catabolism 8

Pharmacologic Ammonia Scavenging

For OTC deficiency specifically, intravenous L-arginine hydrochloride is critical as it replaces the deficient urea cycle intermediate. 8

• L-arginine hydrochloride dosing for OTC deficiency:

  • Body weight <20 kg: 200 mg/kg over 90 minutes as bolus, then maintenance over 24 hours
  • Body weight >20 kg: 4 g/m² over 90 minutes as bolus, then maintenance over 24 hours 8

• Nitrogen scavengers (sodium benzoate and/or sodium phenylacetate):

  • Body weight <20 kg: 250 mg/kg
  • Body weight >20 kg: 5.5 g/m²
  • Given over 90–120 minutes as bolus then maintenance over 24 hours
  • Maximum sodium benzoate dose 12 g daily (high doses can be toxic and lethal within 1 hour) 8

Renal Replacement Therapy Indications

Hemodialysis should be initiated for rapidly rising ammonia levels >300 µmol/L within hours or persistently elevated levels >400 µmol/L refractory to medical management. 8, 5

• Intermittent hemodialysis removes ammonia more rapidly than peritoneal dialysis and is preferred when available 8
• Peritoneal dialysis is recommended only when extracorporeal therapies are unavailable or unsafe; rigid catheters should be avoided due to increased complications 8
• Continuous kidney replacement therapy (CKRT) provides sustained ammonia clearance in critically ill patients 8

Long-Term Management

Chronic treatment with sodium phenylbutyrate or glycerol phenylbutyrate combined with protein restriction and L-citrulline supplementation reduces hyperammonemic episodes and prevents cognitive decline. 9, 10

Maintenance Therapy

• Sodium phenylbutyrate or sodium phenylacetate activates alternative pathways of waste-nitrogen excretion, reducing hyperammonemic episodes with increasing age 9
• Protein-restricted diet (typically 1.5 g/kg daily or less) is essential for long-term control 2, 10
• L-citrulline supplementation bypasses the OTC enzyme defect by providing substrate for downstream urea cycle steps 10
• Essential amino acid supplements may be needed to prevent malnutrition while maintaining protein restriction 10

Monitoring and Outcomes

• Monthly laboratory assessments including plasma ammonia and amino acids are critical, especially during high-risk periods 10
• Girls with symptomatic OTC deficiency treated with nitrogen-scavenging drugs have >90% five-year survival and stable IQ scores when treatment is maintained 9
• Morbidity from brain damage does not appear directly linked to the number of hyperammonemic episodes, emphasizing the importance of prevention 2

High-Risk Situations Requiring Intensified Monitoring

• Pregnancy and postpartum period carry increased risk of hyperammonemia in female carriers; multidisciplinary obstetric management is essential 10
• Fasting states (including preoperative periods), surgery, infections, and metabolic stress can precipitate crises 4, 10
• Medications such as valproic acid and corticosteroids can trigger hyperammonemia and should be avoided 1, 2

Definitive Treatment

Liver transplantation should be considered when symptoms are life-threatening or refractory to medical management, though severe complications may occur 2